Healthcare investment firm Vivo Capital leads $55m round in Beijing Innocare

Healthcare investment firm Vivo Capital has led the $55-million funding round of Beijing Innocare, a biopharmaceutical company that develops treatment for cancer and autoimmune diseases, with CCB Capital also backing the round.

In a statement posted on its Chinese website, Beijing Innocare confirmed closing the $55-million funding round, which it said will be used to “promote innovation in drug research and development to serve the needs of Chinese patients”.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter